Calcium Channel Blocker Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Calcium Channel Blocker Market is segmented By Drug Class (Dihydropyridine, Phenylalkylamine, Benzothiazepine), By Distribution Channel and Geography.

Calcium Channel Blocker Market Snapshot

calcium channel blocker market snapshot
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 5.1 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Calcium Channel Blocker Market is expected to register a CAGR of 5.1 % during the forecast period. The increasing prevalence rate of cardiovascular diseases and changing lifestyle of people is expected to boost the calcium channel blocker market growth. Hypertension often referred as the elevated blood pressure is one of the major causes associated with heart diseases. According to World Health Organization, approximately 1.13 billion of people globally have hypertension. Furthermore, cardiovascular diseases are one of the leading causes of the death and around 17.9 million people died in 2016 due to it. Calcium antagonist are known to be effective against this indication. Thus, the demand has been steadily growing for this market for better management of the cardiovascular diseases. However, the recent years, also observed some cases related to product recalls which restricts the growth of the studied market.

Scope of the Report

Calcium Channel blockers/ Calcium antagonists are drugs that are used against indications such as hypertension and chest pain. It slows the calcium movement that helps to widen the blood vessels and makes it easier for heart to pump the blood.  Calcium Channel Blocker Market is segmented By Drug Class, Distribution Channel and Geography.

By Drug Class
Dihydropyridine
Benzothizepine
Phenylalkylamine
By Distribution Channel
Hospitals
Retail Pharmacies
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Dihydropyridines Segment is Expected to Hold a Major Share in the Calcium Channel Blocker Market

  • Though the mechanism of action is similar in all the classes, the pharmacological effects vary. Dihydropyridine is known to exhibit more vasodilation and less negative ionotropic effect in sinoatrial and atrioventricular nodes.
  • Also, dihydropyridine calcium channel blockers are majorly prescribed over others in most of the Asia-Pacific region, as reported by the study of Journal of Clinical Hypertension, 2016.
  • Moreover, the fourth generation dihydropyridine drug, cilnidipine is considered as an effective treatment against autonomic dysfunction which is a key risk factor for atrial fibrillation. It inhibits L-type calcium as well as N-type of calcium, and are able to dilate efferent and afferent arteriole effectively. Hence, these factors are expected to propel the dihydropyridine segment of calcium Channel blocker market.
Calcium Channel Blocker Market Trends Images.png

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America expected to hold a major market share in the global calcium Channel blocker market due to changing lifestyle among people and increasing prevalence rate of cardiovascular diseases. The adoption of sedentary lifestyle has serious implications on the health of people and are known to cause diseases related to cardiovascular diseases, obesity, high blood pressure, etc. According to the World Health Organization, around 60% - 85% of people, worldwide, have adopted a sedentary life. According to Centre for Disease Control and Prevention, around 31 million adults aged over 50 years lives a sedentary life, and only 1 out of 4 US adults & 1 out 5 school student meets the guideline of physical activity. Heart disease is one of the leading causes of death in U.S., at least one person dies every 37 second due to cardiovascular disease, as reported by Centre for Disease Control and Prevention.  

Calcium Channel Blocker Market - Growth Rate by Region

Competitive Landscape

The Calcium Channel Blocker Market is fragmented and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Pfizer Inc, Alvogen, Abbvie Inc, Exela, Pharma Sciences, LLC, Bausch Health Company Inc., GlaxoSmithKline LLC, Silvergate Pharmaceuticals Inc., Novartis AG, Covis Pharma BV, Arbor Pharmaceuticals LLC.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Burden of Cardiovascular Diseases

      2. 4.2.2 Changing Lifestyle of People

    3. 4.3 Market Restraints

      1. 4.3.1 Product Recalls

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug Class

      1. 5.1.1 Dihydropyridine

      2. 5.1.2 Benzothizepine

      3. 5.1.3 Phenylalkylamine

    2. 5.2 By Distribution Channel

      1. 5.2.1 Hospitals

      2. 5.2.2 Retail Pharmacies

      3. 5.2.3 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Abbvie Inc

      2. 6.1.2 Alvogen

      3. 6.1.3 Arbor Pharmaceuticals LLC

      4. 6.1.4 Bausch Health Company Inc.

      5. 6.1.5 Covis Pharma BV

      6. 6.1.6 Exela Pharma Sciences, LLC

      7. 6.1.7 GlaxoSmithKline LLC

      8. 6.1.8 Novartis AG

      9. 6.1.9 Pfizer Inc

      10. 6.1.10 Silvergate Pharmaceuticals Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Calcium Channel Blocker Market market is studied from 2018 - 2026.

The Calcium Channel Blocker Market is growing at a CAGR of 5.1% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Pfizer Inc., Abbvie Inc., Silvergate Pharmaceuticals Inc., Covis Pharma BV​ , Novartis AG are the major companies operating in Calcium Channel Blocker Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!